Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Eupraxia Pharmaceuticals Inc

Healthcare CA EPRX

8.87CAD
0.00(0%)

Last update at 2026-06-04T18:18:00Z

Day Range

8.599.11
LowHigh

52 Week Range

5.0112.86
LowHigh

Fundamentals

  • Previous Close 8.87
  • Market Cap592.28M
  • Volume93096
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-38.26964M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-1.41

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -39.26204M -35.26649M -39.18471M -23.91722M -23.36955M
Minority interest 0.03M 0.24M 0.75M 0.66M 0.38M
Net income -39.25144M -34.93749M -37.39171M -23.25937M -22.98961M
Selling general administrative 17.10M 15.71M 9.65M 5.53M 8.41M
Selling and marketing expenses - - 0.14M - -
Gross profit -0.24188M -0.23525M -0.20991M - -
Reconciled depreciation 0.24M 0.17M 0.16M 0.19M 0.11M
Ebit -39.10685M -33.95248M -37.60534M -23.20393M -18.19966M
Ebitda -38.86497M -33.71723M -37.39543M -22.13558M -21.96133M
Depreciation and amortization 0.24M 0.24M 0.21M - -
Non operating income net other - - - - -
Operating income -39.10685M -36.99363M -36.89674M -23.23561M -20.96741M
Other operating expenses 39.11M 36.99M 37.92M - -
Interest expense 0.00000M 1.31M 1.58M 1.59M 1.30M
Tax provision 0.02M 0.00180M 0.04M - -
Interest income 1.41M 1.24M 0.86M 0.67M 2.40M
Net interest income 1.41M 0.56M -0.30720M -1.01904M -1.23096M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.02M 0.00247M -0.08967M - -
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 38.86M 36.76M 37.92M 23.20M 18.68M
Cost of revenue 0.24M 0.24M 0.21M - -
Total other income expense net -0.15519M 1.73M -2.28796M 0.31M -3.46091M
Discontinued operations - - - - -
Net income from continuing ops -38.60565M -25.74449M -28.96601M -23.91721M -23.36955M
Net income applicable to common shares - -25.50254M -28.22080M -23.25937M -22.98961M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 85.99M 34.94M 26.72M 25.88M 31.22M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 3.85M - 0.36M - -
Total liab 5.69M 3.10M 25.55M 13.02M 10.84M
Total stockholder equity 81.89M 33.40M 2.92M 12.86M 20.39M
Deferred long term liab - - - - -
Other current liab 5.54M - 11.76M - 0.00501M
Common stock 195.05M - 122.52M 92.34M 80.71M
Capital stock 225.15M 148.07M 92.91M 92.34M 80.71M
Retained earnings -169.27136M -131.00383M -139.11401M -97.44614M -74.18676M
Other liab - - - - -
Good will - - - - -
Other assets - - 0.00000M 0.00337M 0.03M
Cash 80.42M 33.10M 25.50M 24.74M 20.89M
Cash and equivalents - - - - -
Total current liabilities 5.62M 3.10M 25.55M 4.14M 2.27M
Current deferred revenue - - - - -
Net debt -80.26279M - -11.72199M - -
Short term debt 0.08M - 13.78M 0.00000M 0.00000M
Short long term debt - - 10.40M 0.11M 0.09M
Short long term debt total 0.15M - 13.78M - -
Other stockholder equity 28.47M - 23.09M 17.96M 13.86M
Property plant equipment - - - 0.70M 0.59M
Total current assets 84.94M 34.44M 26.11M 25.18M 30.60M
Long term investments - - - - -
Net tangible assets - - - 12.86M 20.39M
Short term investments - - - 0.00000M 9.01M
Net receivables 0.67M - 0.25M 0.12M 0.43M
Long term debt - - - 10.30M 9.26M
Inventory - - 0.00000M - -
Accounts payable - - - - -
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -2.04042M - -3.56886M - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.06M - 0.00910M - -
Deferred long term asset charges - - - - -
Non current assets total 1.05M 0.51M 0.61M 0.70M 0.62M
Capital lease obligations 0.15M 0.07M 0.05M 0.14M 0.20M
Long term debt total - - - 10.37M 9.40M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.07516M -0.07338M 9.01M -9.00000M
Change to liabilities - - - 1.78M -0.46748M
Total cashflows from investing activities -0.59926M -0.07516M -0.09903M 8.70M -14.44982M
Net borrowings 0.00000M -9.13746M -0.07944M -0.18518M 12.08M
Total cash from financing activities 77.39M 45.78M 27.84M 13.52M 49.92M
Change to operating activities - - - -0.02053M 0.07M
Net income -39.25144M -25.74449M -37.39171M -23.25937M -22.98961M
Change in cash 45.75M 13.76M 1.08M 3.84M 20.74M
Begin period cash flow 34.67M 19.34M 18.26M 20.89M 0.15M
End period cash flow 80.42M 33.10M 19.34M 24.74M 20.89M
Total cash from operating activities -29.05204M -29.99449M -27.91642M -18.77643M -14.64163M
Issuance of capital stock 73.89M 54.56M 15.89M 13.30M 37.83M
Depreciation 0.24M 0.24M 0.16M 0.19M 0.11M
Other cashflows from investing activities - 0.03M -0.00181M 9.01M -5.01815M
Dividends paid - - - - -
Change to inventory - - -0.57791M - -
Change to account receivables -0.43900M -0.10139M -0.13998M 0.31M 0.19M
Sale purchase of stock - 54.92M 21.16M 13.71M 37.83M
Other cashflows from financing activities - 0.36M 12.10M - 0.00000M
Change to netincome - - - 2.22M 8.45M
Capital expenditures 0.60M 0.10M 0.07M 0.31M 0.43M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.72619M -6.76469M 6.33M 2.07M -0.17626M
Stock based compensation 9.04M 3.22M 1.41M 2.02M 4.21M
Other non cash items 10.68M -0.94403M 1.58M 1.16M 3.41M
Free cash flow -29.65130M -30.09872M -28.01545M -19.08480M -15.07330M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (CAD) Price (CAD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
EPRX
Eupraxia Pharmaceuticals Inc		 - -% 8.87 - - - 8.45 -3.8823
FRX
Fennec Pharmaceuticals Inc		 -1.04 7.56% 12.72 - 21.01 6.95 6.35 4.25 20.27
MSCL
Satellos Bioscience Inc.		 -0.01 0.12% 8.30 - - - 5.85 6.47
HBP
Helix BioPharma Corp.		 - -% 1.58 - 3.87 4263.36 9.74 4422.35 -6.3589
SVA
Sernova Corp		 -0.005 3.12% 0.15 - - 65.86 24.15 36.69 -11.2729

Reports Covered

Stock Research & News

View All

Profile

Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company's product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of gastrointestinal tract, such as eosinophilic esophagitis. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.

Eupraxia Pharmaceuticals Inc

2067 Cadboro Bay Road, Victoria, BC, Canada, V8R 5G4

Key Executives

Name Title Year Born
Dr. James A. Helliwell FRCPC, M.D. CEO & Director 1974
Mr. Bruce G. Cousins CPA, C.A., CPA Pres & CFO 1961
Dr. Amanda Malone Ph.D. Chief Scientific Officer 1981
Mr. Paul Anthony Brennan B.Sc., M.Sc. Chief Bus. Officer NA
Mr. Bruce G. Cousins C.A., CPA President & CFO 1961
Dr. Amanda Malone Ph.D. Chief Scientific Officer & COO 1981
Mr. Paul Anthony Brennan B.Sc., M.Sc. Chief Business Officer NA
Dr. Mark M. Kowalski M.D., Ph.D. Chief Medical Officer 1955
Dr. Rahul Sarugaser M.B.A., Ph.D. Executive Vice President of Corporate Development NA
Mr. Alexander John Rothwell Eng., M.B.A. Chief Financial Officer 1969

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.